Overview

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

Status:
Recruiting
Trial end date:
2020-10-30
Target enrollment:
0
Participant gender:
All
Summary
Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Turin, Italy
Treatments:
Canagliflozin
Dapagliflozin
Empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
Criteria
Inclusion Criteria:

- diabetic patients;

- clinical indication to SGLT2i therapy.

Exclusion Criteria:

- signs and symptoms of poor glycemic control (polydipsia, polyuria and weight loss);

- HbA1c >10% or 86 mmol/mol;

- Body Mass Index (BMI) > 40 Kg/m2;

- personal history of primary and secondary aldosteronism;

- personal history of heart failure;

- personal history of acute kidney injury;

- personal history of chronic kidney disease;

- personal history of liver cirrhosis;

- personal history of protein-wasting syndrome;

- personal history of renin secreting tumor;

- personal history of diabetes insipidus;

- personal history of syndrome of inappropriate antidiuresis (SIAD);

- personal history of hypocortisolism and hypercortisolism;

- therapy with Angiotensin Converting Enzyme inhibitors;

- therapy with Angiotensin Receptor Blockers;

- therapy with renin inhibitors;

- therapy with beta-blockers;

- therapy with alfa2-receptors agonists;

- therapy with Calcium Channel Blockers;

- therapy with diuretics;

- therapy with mineralocorticoid receptor antagonists;

- therapy with non steroidal and steroidal anti-inflammatory drugs.